Palisade Bio Inc

PALI | $4.735 -6.61% -7.07% 140K

(0.0% 1d) (1644.6% 1m) (275.0% 1y) (0.0% 2d) (0.0% 3d) (60.8% 7d) (-94.59% volume)
Earnings Calendar: 2022-11-11
Market Cap: $ 60,470,756
https://www.palisadebio.com
Sec Filling | Patents | n/a employees

(US) Palisade Bio is a late-stage biopharma company advancing therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. Palisade Bio’s innovative lead asset, LB1148, is a Phase 3-ready protease inhibitor with the potential to both reduce abdominal adhesions and help restore bowel function following surgery. Positive data from Phase 2 trials of LB1148 demonstrated safety and tolerability as well as a statistically significant improvement in return to bowel function and decrease in length of stay in ICU and hospital compared to placebo. Palisade Bio believes that its investigational therapies have the potential to address the myriad health conditions and complications associated with chronic disruption of the gastrointestinal epithelial barrier.

education msa gastrointestinal

add to watch list Paper trade email alert is off

Theriva Biologics Inc

TOVX | $0.4152 -7.32% 0.0% 60K

Manufacturing

(0.0% 1d) (-30.3% 1m) (-39.4% 1y) (0.0% 2d) (0.0% 3d) (-0.7% 7d) (48.5% volume)
Earnings Calendar:
Market Cap: $ 7,119,870
https://www.syntheticbiologics.com
Sec Filling | Patents | 10 employees

(US) Synthetic Biologics, Inc. is a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need. The Company's lead candidates are: (1) SYN-004 (ribaxamase) which is designed to degrade certain commonly used intravenous (IV) beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent (a) microbiome damage, (b) Clostridioides difficile infection (CDI), (c) overgrowth of pathogenic organisms, (d) the emergence of antimicrobial resistance (AMR), and (e) acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients, and (2) SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases.

urea gastrointestinal injection t-cell pathogens

add to watch list Paper trade email alert is off

First Wave BioPharma, Inc.

FWBI | $2.59 -8.8% -9.65% 83K

Manufacturing

(0.0% 1d) (-38.7% 1m) (5.2% 1y) (0.0% 2d) (-2.1% 3d) (-13.1% 7d) (-24.56% volume)
Earnings Calendar: 2022-11-14
Market Cap: $ 5,245,265
https://www.azurrx.com
Sec Filling | Patents | 12 employees

(US) AzurRx BioPharma, Inc. is a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The Company has a pipeline of three gut-restricted GI assets. The lead therapeutic candidate is MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis and chronic pancreatitis, currently in two Phase 2 clinical trials. AzurRx is launching two clinical programs using proprietary formulations of niclosamide, a pro-inflammatory pathway inhibitor, FW-420, for grade 1 Immune Checkpoint Inhibitor Colitis and diarrhea in oncology patients and FW-1022, for COVID-19 gastrointestinal infections. The Company is headquartered in Delray Beach, Florida with clinical operations in Hayward, California.

covid disease treatment phase 2 biopharma diarrhea fibrosis clinical trials test gastrointestinal trials trial pancreatic injection

add to watch list Paper trade email alert is off